Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Preferred Shares: 2023-2025

Historic Preferred Shares for SAB Biotherapeutics (SABS) over the last 2 years, with Sep 2025 value amounting to $64.

  • SAB Biotherapeutics' Preferred Shares rose 1180.00% to $64 in Q3 2025 from the same period last year, while for Sep 2025 it was $64, marking a year-over-year increase of 1180.00%. This contributed to the annual value of $5 for FY2024, which is negligibly% changed negligibly from last year.
  • Per SAB Biotherapeutics' latest filing, its Preferred Shares stood at $64 for Q3 2025, which was up 1,180.00% from $5 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Preferred Shares ranged from a high of $64 in Q3 2025 and a low of $5 during Q4 2023.
  • For the 3-year period, SAB Biotherapeutics' Preferred Shares averaged around $12.38, with its median value being $5 (2025).
  • Data for SAB Biotherapeutics' Preferred Shares shows a peak YoY spiked of 1,180.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows SAB Biotherapeutics' Preferred Shares stood at $5 in 2023, then remained steady at $5 in 2024, then soared by 1,180.00% to $64 in 2025.
  • Its last three reported values are $64 in Q3 2025, $5 for Q2 2025, and $5 during Q1 2025.